Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several new combination therapies have been approved for the treatment of COPD, further increasing the competition. Although these new therapies perform well on a variety of clinical end points, most offer only incremental improvements, and none have yet demonstrated a statistically significant decrease in all-cause mortality. Owing to the high level of unmet need in COPD, significant clinical and commercial opportunity remains for therapies that can provide a decrease in all-cause mortality, number of exacerbations, or improvement on several clinically important end points, including FEV1 and frequency of exacerbations, compared with current standards of care.
Already a Client? Log in to access this report.
Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.